Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience.

Indian journal of cancer·2017
Same author

Comparison of Rai and Binet Classifications in Chronic Lymphocytic Leukemia.

Hematology (Amsterdam, Netherlands)·2016
Same author

A new prognostic strategy for gastric carcinoma: albumin level and metastatic lymph node ratio.

Minerva chirurgica·2014
Same author

Successful treatment of myeloid sarcoma with local treatment modalities: the longest overall survival in published literature.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2014
Same author

Changes in plasma amino acids during conditioning therapy prior to bone marrow transplantation: Their relevance to antioxidant status.

Amino acids·2013
Same author

What is the most fearful intervention in ambulatory oral surgery? Analysis of an outpatient clinic.

International journal of oral and maxillofacial surgery·2012

Related Experiment Video

Updated: Mar 18, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Granulocyte-Colony Stimulating Factor (G-CSF) Administration for Chemotherapy-Induced Neutropenia.

Ş Yalçin1, N Güler1, E Kansu1

  • 1a Hacettepe University, Institute of Oncology , Ankara , Turkey.

Hematology (Amsterdam, Netherlands)
|July 14, 2016
PubMed
Summary

Granulocyte colony-stimulating factor (G-CSF) effectively speeds neutrophil recovery in patients with neutropenia after chemotherapy. This study found G-CSF accelerated neutrophil count recovery without increasing infection rates in acute myeloid leukemia patients.

Keywords:
Acute LeukemiaFebrile NeutropeniaG-CSFSolid Tumor

More Related Videos

Colony Forming Cell CFC Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell CFC Assay for Human Hematopoietic Cells

Published on: December 18, 2010

36.5K
Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
12:02

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

4.7K

Related Experiment Videos

Last Updated: Mar 18, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K
Colony Forming Cell CFC Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell CFC Assay for Human Hematopoietic Cells

Published on: December 18, 2010

36.5K
Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
12:02

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

4.7K

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Neutropenia is a common side effect of intensive chemotherapy, increasing infection risk.
  • Granulocyte colony-stimulating factor (G-CSF) is used to mitigate neutropenia.
  • Evaluating G-CSF efficacy in specific chemotherapy regimens is crucial.

Purpose of the Study:

  • To assess the efficacy of G-CSF in accelerating neutrophil recovery in patients with neutropenia post-chemotherapy.
  • To evaluate G-CSF's impact on infection rates in acute myeloid leukemia (AML) patients.

Main Methods:

  • A study involving 37 patients with neutropenia receiving G-CSF after intensive chemotherapy (ifosfamide/etoposide or mitoxantrone/cytarabine).
  • A control group of 31 AML patients.
  • G-CSF administration initiated on day 1 of neutropenia, continued until neutrophil count exceeded 1000/mm³ for two consecutive days.

Main Results:

  • G-CSF demonstrated effectiveness in the early recovery of neutrophil counts.
  • 91.5% of treatment courses achieved the expected response within 14 days, with a median recovery on the fifth day of G-CSF treatment.
  • No significant reduction in febrile episodes or documented bacterial/fungal infections was observed.

Conclusions:

  • G-CSF is effective in accelerating neutrophil recovery in neutropenic patients undergoing intensive chemotherapy.
  • While G-CSF aids neutrophil count recovery, it did not reduce the incidence of febrile episodes or documented infections in AML patients.
  • Further research may be needed to explore strategies for reducing infection rates alongside G-CSF therapy.